Multiple Sclerosis Drugs Market 2021 Growth Drivers, Business Strategies and Future Prospects: Biogen, Sanofi, Novartis, Teva, Merck KGaA, Bayer, ACORDA, Mallinckrodt

Multiple Sclerosis Drugs Market Report provides detailed analysis of Growth Factors of the market as well as it gives an analysis of the Market size, Latest trends, SWOT Analysis by Regions and Forecasted market research data until 2026. The Multiple Sclerosis Drugs market report has studied key opportunities in the market and influencing factors which are useful to the business. The report also maps the qualitative and quantitative impact of various market factors like macro-economic indicators, PPP, Epidemiological data, Insurance scenario and patent and IP information, Government Policies and business regulations along market attractiveness as per segments.

Multiple Sclerosis Drugs size is estimated to be xx million in 2021 from USD 15030 million in 2020, with a change of XX% between 2020 and 2021. The global Multiple Sclerosis Drugs market size is expected to grow at a CAGR of 4.8% for the next five years. 

Get Sample Copy Of This Report + All Related Graphs (Covid-19 Update):

https://www.marketinsightsreports.com/reports/03232743914/global-multiple-sclerosis-drugs-market-2021-by-manufacturers-regions-type-and-application-forecast-to-2026/inquiry?source=Openpr&Mode=Twelve                                       

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Multiple Sclerosis Drugs Market: Biogen, Sanofi, Novartis, Teva, Merck KGaA, Bayer, ACORDA, Mallinckrodt and others.

Industry News and Developments:

Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 -- Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Biogen holds the exclusive, worldwide license to commercialize VUMERITY and intends to make it available in the United States in the near future.

“The FDA’s approval of VUMERITY delivers on Biogen’s commitment to pursue new therapies that may provide meaningful impact for people living with relapsing MS, and we look forward to bringing it to the MS community as an additional treatment option,” said Alfred Sandrock, Jr., M.D., Ph.D., executive vice president, research and development, and chief medical officer at Biogen. “VUMERITY is a novel fumarate that offers the well-characterized efficacy of TECFIDERA (dimethyl fumarate) and has been studied for improved patient-reported gastrointestinal tolerability.”

“The approval of VUMERITY for relapsing MS marks the culmination of a multi-year development program and is the latest milestone in our mission to develop new treatments for patients living with chronic central nervous system disorders,” said Craig Hopkinson, M.D., chief medical officer and senior vice president of medicines development and medical affairs at Alkermes. “We are grateful to the patients and study investigators who have participated in our VUMERITY clinical trials and we look forward to working with our collaboration partners at Biogen to make this new treatment available to patients.”

Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

CAMBRIDGE, Mass., April 15, 2021 -- Biogen Inc. (Nasdaq: BIIB) today announced that China’s National Medical Products Administration (NMPA) has approved TECFIDERA® (dimethyl fumarate) for the treatment of relapsing multiple sclerosis (MS). First introduced in 2013, TECFIDERA has demonstrated a well-established safety and efficacy profile with more than 10 years of data from clinical trials and real-world experience.1 It has been used to treat more than 500,000 individuals with MS worldwide.1 The approval brings a new treatment option to people in China living with relapsing MS and also continues to expand the company’s presence in the country.

“It is truly a milestone to bring this well-established treatment to China and be able to help people living with relapsing multiple sclerosis,” said Rachid Izzar, President, Intercontinental Region at Biogen. “We thank the NMPA for undertaking priority review to approve TECFIDERA. We are committed to expanding our presence in China and working with the MS community to address unmet medical needs through innovative therapies and solutions.”

The NMPA evaluation was based on data from the global, pivotal Phase 3 DEFINE and CONFIRM studies, which enrolled more than 2,600 patients. In DEFINE, TECFIDERA administered twice daily significantly reduced the annualized relapse rate by 53 percent compared to placebo, at two years. In CONFIRM, twice-daily TECFIDERA significantly reduced the proportion of patients who relapsed by 34 percent compared to placebo at two years.

Global Multiple Sclerosis Drugs Market Split by Product Type and Applications:

On the basis of Types, the market is segmented into:

Injectable Medications
Oral Medications
Others

On the basis of Application, the market is segmented into:

Adults
Children

Buy The Multiple Sclerosis Drugs Market Report:
https://www.marketinsightsreports.com/report/purchase/03232743914?mode=su?source=Openpr&Mode=Twelve                   

Regional analysis:

This report covers South America, North America, Europe, Asia Pacific (APAC), Africa and The Middle East, taking into account the clear evidence of where the market is fully examined, typical market examples, blocks and open access roads for power generation. With a huge population, Asia Pacific has revenues in the picture year, and dominates the Multiple Sclerosis Drugs market share, at any given time. Continuous GDP reform; Institutional progress per capita is becoming urbanized in the metropolitan area. This expanded revenue has led to indulging in top private and unrealistic usage models in the Multiple Sclerosis Drugs market deployed in the region. While an important piece of the Multiple Sclerosis Drugs market center around the global expansion of business, territories such as the Middle East and Africa will grow steadily. Big market development will take place in Latin America because of the small expansion producers' attempts at profits. In Europe, a lethargic improvement is expected due to mood-oriented rules and early stages.

Key Points of Multiple Sclerosis Drugs Market Table of Contents:

-Market Overview: The report begins with this section where a product overview and key content on the product and application segments of the global Multiple Sclerosis Drugs market are provided. The highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

-Competition by company: Here we analyze the competition of the global Multiple Sclerosis Drugs market, by company price, revenue, sales and market share, market share, competitive landscape, and latest trends, mergers, expansions, acquisitions, and market share of top companies.

-Company Profile and Sales Data: As the name suggests, this section provides sales data and useful information about the business of key players in the global Multiple Sclerosis Drugs market. It describes the key businesses of gross margin, price, revenue, products and specifications, types, applications, competitors, manufacturing base, and key players operating in the global Multiple Sclerosis Drugs market.

-Market Forecast: Here the report provides a full forecast for the global Multiple Sclerosis Drugs market by product, application, and region. It also provides global sales and revenue forecasts for all years in the forecast period.

-Research Results and Conclusion: One of the last sections of the report where analyst findings and findings are provided.

What are the new revenue channels which companies can explore for growth?       

For More Information On This Report, Please Visit: https://www.marketinsightsreports.com/reports/03232743914/global-multiple-sclerosis-drugs-market-2021-by-manufacturers-regions-type-and-application-forecast-to-2026?source=Openpr&Mode=Twelve                                    

Due to the onset of COVID-19 pandemic, several economies across the world have experienced harsh economic downturn. The industrialists across North America, Europe, Asia Pacific, Latin America and Middle East and Africa were facing problems due to changing preferences of the customers and demand fluctuation. The market research report covers pre-Covid-19 data for the Multiple Sclerosis Drugs market in years 2018 and 2020. Further, the report also covers forecast Covid-19 data from 2021 to 2026, which provides future outlook of the market for the manufacturers and suppliers.

Browse Related Reports:

Amyotrophic Lateral Sclerosis Therapeutics Market:  

https://www.marketinsightsreports.com/reports/07073049301/global-amyotrophic-lateral-sclerosis-therapeutics-market-size-status-and-forecast-2021-2027?source=Openpr&Mode=Twelve                                          

Systemic Sclerosis Treatments Market:

https://www.marketinsightsreports.com/reports/07063039064/global-systemic-sclerosis-treatments-market-size-status-and-forecast-2021-2027?source=Openpr&Mode=Twelve                                              

Relapsing Multiple Sclerosis Treatment Market:

https://www.marketinsightsreports.com/reports/06293018971/global-relapsing-multiple-sclerosis-treatment-market-size-status-and-forecast-2021-2027?source=Openpr&Mode=Twelve                                       

Customization Of The Report:

MarketInsightsReports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.     

If you have any questions about any of our “Multiple Sclerosis Drugs market report” or would like to schedule a personalized free demo of Multiple Sclerosis Drugs market report, please do not hesitate to contact me at irfan@marketinsightsreports.com.

Best wishes,

Irfan Tamboli

Head of Sales Operations

Market Insights Reports

Tel: + 1704 266 3234 | +91-750-707-8687

Email: sales@marketinsightsreports.com | irfan@marketinsightsreports.com

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides Global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.